GlassScriptPhysician profile
Francis D Pien
NPI 1376540617
$9,951.11
in general payments reported to CMS, 2019-2025
20 companies · $1,715 in 2025
The $1,715 reported for 2025 was more than what 84% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,398 · 2020: $756 · 2021: $1,117 · 2022: $2,266 · 2023: $1,415 · 2024: $1,284 · 2025: $1,715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,378 · Education: $36.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,377.62 |
| Education | $36.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $1,922.56 | 2019-2025 | Arikayce |
| Abbvie INC. | $1,734.54 | 2021-2025 | |
| Gilead Sciences, INC. | $1,715.54 | 2019-2025 | Biktarvy, Yeztugo, Sunlenca |
| Viiv Healthcare Company | $1,188.02 | 2021-2025 | Apretude, Dovato, Cabenuva |
| Novo Nordisk INC | $694.87 | 2019-2025 | Ozempic |
| Shionogi INC | $379.52 | 2024-2025 | Fetroja |
| Janssen Biotech, INC. | $355.12 | 2020-2022 | |
| Janssen Products, LP | $314.76 | 2021-2022 | |
| Allergan, INC. | $289.79 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $280.20 | 2019-2025 | Capvaxive, Pifeltro |
| Astellas Pharma US INC | $242.21 | 2019 | |
| Emd Serono, INC. | $222.29 | 2020-2024 | Serostim |
| Cumberland Pharmaceuticals, INC. | $215.68 | 2022-2025 | Vibativ |
| Amarin Pharma, INC. | $145.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $112.80 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $47.66 | 2021 | |
| Smith+Nephew, INC. | $37.35 | 2019 | |
| Ferring Pharmaceuticals INC. | $24.20 | 2023 | Rebyota |
| Paratek Pharmaceuticals, INC. | $15.60 | 2021 | |
| Lilly USA, LLC | $13.40 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Pien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.